济南痛风发作时能降尿酸吗(山东痛风几级疼痛) (今日更新中)

Beijing, Sept. 13 (Xinhuanet) -- A fear of taking antidepressants often results in people's reluctance of going to see the doctor when they are suffering from depression, a study find.The finding was published Monday in the U.S. journal Annals of Family Medicine.The researchers from the University of California investigated 1,054 adults on why they wouldn't tell the doctors about their depression symptoms, as well as any possible mental disorder.Among the participants, 43 percent admitted that they had been reluctant to tell the doctor about their depression symptoms.Their top concern was the possibility of being prescribed an antidepressant -- a worry voiced by 23 percent of the whole study group.Another 16 percent thought dealing with "emotional issues" is not the doctor's job. And a similar percentage worried that the diagnosis of depression may leave a negative record on their medical records.The study would be helpful for looking into the reasons that patients harbor the attitudes that they do, said Dr. Hellerstein of the New York State Psychiatric Institute and Columbia University Medical Center in New York.

RIO DE JANEIRO, July 28 (Xinhua) -- Brazilians are eating a lot of rice and beans as well as high-calorie junk food lacking nutrition, a study released Thursday by the Brazilian Institute of Geography and Statistics (IBGE) found.According to the study, over 90 percent of Brazilians eat daily helpings of fruits and vegetables lower than the levels recommended by the Health Ministry (400 grams). Also,the consumption of sugary drinks (juices, fruit drinks and soft drinks) is twice as high as recommended by the ministry.Rice and beans, along with coffee and juices, are the most popular in Brazilians' diet. Teenagers are the main consumers of those drinks, drinking twice as much as adults. Men eat less greens and fruits than women, but drink five times more alcohol.In urban areas, the consumption of beer, soft drinks, sandwiches, and salty bread is higher. Brazilians in rural areas have a healthier diet, richer in rice, beans, fish, cassava flour, and sweet potatoes.Along with a lack of physical activity, the Brazilians' poor diet was cited as one of the main causes of obesity in the country. According to a Health Ministry study published in April, 48 percent of Brazilians are overweight, and 15 percent are obese.

MOSCOW, Aug. 3 (Xinhua) -- Two Russian cosmonauts manually launched a mini satellite from the International Space Station ( ISS) during a six-hour spacewalk Wednesday, said the Mission Control center near Moscow.Sergei Volkov and Alexander Samokutyayev, who started the spacewalk with a 20-minute delay, found the 30-kg Kedr has lost one of its two antennas during its delivery to the ISS in January. After consulting with the Mission Control, they have decided to launch the device anyway, Interfax news agency reported.The Kedr satellite, which was made by Russian students, was created to transmit from the orbit greetings in 15 languages about the 50th anniversary of Yuri Gagarin's first space flight. It could also photograph the Earth and re-transmit information from the ISS equipment.During the spacewalk, the cosmonauts were expected to install new stream video equipment on the station's outer surface, and to take pictures holding photos of the founders of Russian space explorations, including Konstantin Tsiolkovski, Sergei Korolyov and Yuri Gagarin.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

URUMQI, Sept. 5 (Xinhua) -- The first China-Eurasia Expo that concluded Monday in Urumqi, capital of northwest China's Xinjiang Uygur Autonomous Region, has clinched trade and technical cooperation contracts worth about 130 billion U.S. dollars, expo organizer said.Among all contracts, 5.5 billion dollars are clinched between Chinese and foreign companies, while 124 billion dollars are among Chinese companies, the organizer said.About 50,000 officials and business people from China and about 30 countries, regions and international organizations attended the trade fair, which also attracted an audience of more than 300,000 people.The event was upgraded from the 19-year-old China Urumqi Foreign Economic Relations and Trade Fair, a regional trade fair, last year.The fair covered an area of nearly 80,000 square meters for its more than 4,000 exhibition booths, according to the organizer.

来源：资阳报